Denise M Ricigliano, NP
Nurse Practitioner · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Denise M Ricigliano’s office at (650) 988-8338 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
California Medical Board record
Licence C12076 · Deceased
Licence status: Deceased · since 1949 · Washington University School of Medicine.
Licensee is deceased.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$44,321
Medicare paid this office $44,321 for 315 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 171 | $19,018 | $75 |
| Long return visit (40+ min) | 88 | $12,299 | $111 |
| Long return visit (40+ min) | 22 | $3,731 | $143 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $3,369 | $99 |
| Return visit (30+ min) | 34 | $2,893 | $80 |
See all 6 services
| Return visit (30+ min) | 171 | $19,018 | $75 |
| Long return visit (40+ min) | 88 | $12,299 | $111 |
| Long return visit (40+ min) | 22 | $3,731 | $143 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $3,369 | $99 |
| Return visit (30+ min) | 34 | $2,893 | $80 |
| Short return visit (20+ min) | 28 | $1,413 | $50 |
Who their Medicare patients are
315 Original Medicare patients in 2024. Average age 77 · Women 50% · Also on Medicaid 15% · Health risk score 1.65. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 73% · Cancer 50% · Diabetes 32% · Coronary heart disease 30% · Chronic kidney disease 23% · Atrial fibrillation 19% · Heart failure 16% · COPD 15% · Depression 14% · Stroke 12% · Dementia 7%.
The office billed $248,381, Medicare allowed $57,874 and paid $44,321; for 531 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 315 | 531 | 77 | 1.65 | $248,381 | $44,321 |
| 2023 | 54 | 78 | 72 | 1.31 | $26,345 | $6,053 |
| 2018 | 168 | 304 | 73 | 2.28 | $64,788 | $16,017 |
| 2017 | 322 | 901 | 73 | 2.06 | $179,684 | $49,685 |
| 2016 | 362 | 16,910 | 74 | 1.82 | $782,461 | $223,084 |
| 2015 | 67 | 1,322 | 73 | 1.72 | $97,729 | $30,040 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 18 | $1,682 | $93 |
| New patient visit (45+ min) | 12 | $1,449 | $121 |
| New patient visit (30+ min) | 13 | $1,066 | $82 |
| Short return visit (20+ min) | 13 | $860 | $66 |
2018: 6 services
| Return visit (30+ min) | 64 | $4,256 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $3,360 | $49 |
| Long return visit (40+ min) | 28 | $2,592 | $93 |
| Short return visit (20+ min) | 62 | $2,488 | $34 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $1,811 | $121 |
| Advance care planning, first 30 minutes | 12 | $693 | $58 |
2017: 8 services
| Return visit (30+ min) | 131 | $16,076 | $72 |
| Short return visit (20+ min) | 180 | $14,071 | $48 |
| Long return visit (40+ min) | 58 | $6,179 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 56 | $4,701 | $48 |
| Biopsy of bone marrow | 33 | $3,993 | $117 |
| Aspiration of bone marrow sample for diagnosis | 32 | $1,887 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $917 | $71 |
| Advance care planning, first 30 minutes | 13 | $722 | $56 |
2016: 17 services
| Injection, denosumab, 1 mg | 36 | $27,086 | None |
| Return visit (30+ min) | 155 | $18,092 | $71 |
| Short return visit (20+ min) | 197 | $14,215 | $48 |
| Long return visit (40+ min) | 78 | $8,571 | $99 |
| Administration of chemotherapy into vein, 1 hour or less | 32 | $4,395 | $94 |
| Injection, palonosetron hcl, 25 mcg | 14 | $3,305 | None |
| Biopsy of bone marrow | 29 | $3,247 | $112 |
| Aspiration of bone marrow sample for diagnosis | 28 | $1,643 | $59 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 21 | $1,154 | $22 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,143 | $50 |
| Injection of drug or substance under skin or into muscle | 46 | $726 | $16 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 15 | $696 | $46 |
| Administration of chemotherapy into vein, each additional hour | 15 | $586 | $20 |
| Injection of additional new drug or substance into vein | 15 | $337 | $16 |
| Injection, heparin sodium, (heparin lock flush), per 10 units | 28 | $263 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $46 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 11 | $9 | None |
2015: 3 services
| Return visit (30+ min) | 35 | $3,098 | $76 |
| Short return visit (20+ min) | 24 | $1,377 | $51 |
| Injection of drug or substance under skin or into muscle | 12 | $217 | $18 |
Drugs they prescribed that Part D paid
$14,367
Pharmacies billed $14,367 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 13% of their Part D prescriptions (25 of 200) in 2024. A higher opioid share than 9 in 10 peers; the typical nurse practitioner clinician is at 0%. Long-acting opioids: 44% of their opioid prescriptions.
185 generic and 15 brand-name prescriptions · $14,367 in drug cost · 18 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ondansetron | 18 | $527 | $28 |
| Lorazepam | 14 | $50 | $3 |
Year by year
| 2024 | 200 | 94 | 13% (25) | 8% | $14,367 |
| 2023 | 128 | 99 | 0% (0) | 23% | $7,349 |
| 2022 | 30 | 13 | 0% (0) | 0% | $5,186 |
| 2019 | 19 | None | 0% (0) | None | $2,981 |
| 2018 | 328 | 93 | 11% (35) | 11% | $25,765 |
| 2017 | 322 | 91 | 24% (77) | 11% | $37,724 |
| 2016 | 289 | 100 | 23% (65) | 14% | $62,303 |
| 2015 | 61 | 33 | None | None | $18,937 |
| 2014 | 315 | 124 | 30% (94) | 17% | $126,788 |
| 2013 | 137 | 73 | 29% (39) | None | $13,786 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Sod Sulf-Potass Sulf-Mag Sulf | 36 | $2,804 | $78 |
| Peg 3350-Electrolyte | 19 | $466 | $25 |
| Omeprazole | 24 | $336 | $14 |
2018: 7 drugs
| Sancuso | 15 | $11,673 | $778 |
| Ondansetron | 48 | $924 | $19 |
| Warfarin | 33 | $503 | $15 |
| Acyclovir | 16 | $113 | $7 |
| Dexamethasone | 12 | $83 | $7 |
| Lorazepam | 30 | $72 | $2 |
| Prednisone | 11 | $55 | $5 |
2017: 6 drugs
| Morphine Sulfate Er | 20 | $1,282 | $64 |
| Ondansetron | 33 | $342 | $10 |
| Warfarin | 18 | $225 | $12 |
| Hydrocodone-Acetaminophen | 22 | $218 | $10 |
| Lorazepam | 27 | $101 | $4 |
| Prednisone | 17 | $80 | $5 |
2016: 4 drugs
| Hydrocodone-Acetaminophen | 15 | $846 | $56 |
| Ondansetron | 29 | $371 | $13 |
| Oxycodone | 12 | $274 | $23 |
| Lorazepam | 35 | $157 | $4 |
2014: 8 drugs
| Morphine Sulfate Er | 26 | $1,552 | $60 |
| Fentanyl | 14 | $1,250 | $89 |
| Hydrocodone-Acetaminophen | 16 | $376 | $23 |
| Ondansetron Odt | 14 | $360 | $26 |
| Morphine Sulfate | 14 | $344 | $25 |
| Tamoxifen Citrate | 12 | $278 | $23 |
| Ondansetron | 12 | $206 | $17 |
| Lorazepam | 26 | $115 | $4 |
2013: 3 drugs
| Morphine Sulfate Er | 12 | $543 | $45 |
| Ondansetron | 18 | $284 | $16 |
| Lorazepam | 15 | $71 | $5 |
Money from drug and device companies
$1,165 in 2025
| 2025 | 11 | 23 | None | $1,165 |
| 2024 | 9 | 14 | None | $859 |
| 2023 | 5 | 22 | $5,700 | $5,996 |
| 2022 | 12 | 31 | $600 | $1,709 |
| 2021 | 8 | 13 | None | $521 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tecvayli | $261 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $145 | 5 payments
|
| GlaxoSmithKline | Ojjaara | $140 | 3 payments
|
| Daiichi Sankyo | Enhertu | $139 | 5 payments
|
| Myriad Genetic Laboratories | Precisetumor | $126 | 1 payment
|
| Stemline Therapeutics | Orserdu | $123 | 1 payment
|
See all 23 published payments
| Daiichi Sankyo | Meals · 2025-11-20 | Datroway | $29 |
| GlaxoSmithKline | Meals · 2025-11-05 | Blenrep | $18 |
| GlaxoSmithKline | Meals · 2025-11-03 | Jemperli | $10 |
| Daiichi Sankyo | Meals · 2025-10-28 | Datroway | $29 |
| Janssen Biotech | Meals · 2025-10-07 | Rybrevant | $112 |
| Merck Sharp & Dohme | Meals · 2025-10-01 | Keytruda | $32 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-18 | Enhertu | $29 |
| Merck Sharp & Dohme | Meals · 2025-05-22 | Keytruda | $30 |
| Daiichi Sankyo | Meals · 2025-05-15 | Enhertu | $25 |
| Janssen Biotech | Meals · 2025-05-13 | Tecvayli | $149 |
| Abbvie | Meals · 2025-05-07 | Imbruvica | $27 |
| Merck Sharp & Dohme | Meals · 2025-05-01 | Keytruda | $34 |
| Abbvie | Meals · 2025-04-22 | Imbruvica | $15 |
| Myriad Genetic Laboratories | Meals · 2025-04-03 | Precisetumor | $126 |
| Daiichi Sankyo | Meals · 2025-04-02 | Enhertu | $30 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-27 | Opdivo | $19 |
| Stemline Therapeutics | Meals · 2025-03-26 | Orserdu | $123 |
| Karyopharm Therapeutics | Meals · 2025-03-13 | Xpovio | $29 |
| GlaxoSmithKline | Meals · 2025-03-12 | Ojjaara | $112 |
| Merck Sharp & Dohme | Meals · 2025-03-06 | Keytruda | $19 |
| Daiichi Sankyo | Meals · 2025-02-14 | Enhertu | $26 |
| Exelixis | Meals · 2025-02-12 | Cabometyx | $112 |
| Merck Sharp & Dohme | Meals · 2025-01-10 | Keytruda | $30 |
See earlier years (2024, 2023, 2022, 2021)
2024: $859
| Genentech | Tecentriq | $158 | 2 payments
|
| ADC Therapeutics America | None | $145 | 1 payment
|
| Abbvie | Epkinly | $125 | 1 payment
|
| Genmab U.S. | Epkinly | $125 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $116 | 1 payment
|
| Novartis Pharmaceuticals | Scemblix | $91 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $63 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $23 | 1 payment
|
| Olympus America | Single-Use Flexible Video Bronchoscope | $13 | 1 payment
|
2023: $5,996
| Myriad Genetic Laboratories | Myrisk | $4,645 | 13 payments
|
| Myriad Women's Health | Myrisk | $1,200 | 2 payments
|
| Novartis Pharmaceuticals | Scemblix | $99 | 5 payments
|
| Seagen | Adcetris | $33 | 1 payment
|
| Genentech USA | None | $18 | 1 payment
|
2022: $1,709
| Myriad Genetic Laboratories | Myrisk | $700 | 6 payments
|
| Janssen Biotech | Erleada | $351 | 5 payments
|
| Amgen | Lumakras | $121 | 5 payments
|
| E.R. Squibb & Sons L.L.C. | Pomalyst | $108 | 1 payment
|
| Incyte | None | $99 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $83 | 4 payments
|
| Seagen | Adcetris | $71 | 3 payments
|
| GlaxoSmithKline | Blenrep | $52 | 1 payment
|
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $39 | 1 payment
|
| Novartis Pharmaceuticals | Kisqali | $32 | 2 payments
|
| Lilly USA | Verzenio | $30 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $24 | 1 payment
|
2021: $521
| Eisai | Lenvima | $118 | 2 payments
|
| Amgen | Evenity | $112 | 1 payment
|
| Lilly USA | Cyramza | $108 | 2 payments
|
| Novartis Pharmaceuticals | Tasigna | $52 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $43 | 2 payments
|
| Myriad Genetic Laboratories | Myrisk | $41 | 1 payment
|
| Seagen | Padcev | $27 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $20 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1073763835
- Licence
- CA 12076California C12076: Deceased
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Nurse practitioner (363L00000X)
- Mailing address
- 100 Wilson Rd Ste 100, Monterey, CA, 93940
- NPI first listed
- 2008-09-29
- NPI last updated
- 2023-12-06
- NPI record certified
- 2023-12-06
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1595 Soquel Dr Ste 210, Santa Cruz, CA, 95065